- Home
- MYNZ vs CANF Comparison
MYNZ vs CANF Comparison
Compare MYNZ & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- CANF
- Stock Information
- Founded
- MYNZ 2021
- CANF 1994
- Country
- MYNZ Germany
- CANF Israel
- Employees
- MYNZ N/A
- CANF N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- CANF Health Care
- Exchange
- MYNZ Nasdaq
- CANF Nasdaq
- Market Cap
- MYNZ 7.2M
- CANF 7.9M
- IPO Year
- MYNZ 2021
- CANF N/A
- Fundamental
- Price
- MYNZ $3.20
- CANF $1.17
- Analyst Decision
- MYNZ Buy
- CANF Strong Buy
- Analyst Count
- MYNZ 2
- CANF 2
- Target Price
- MYNZ $14.00
- CANF $14.00
- AVG Volume (30 Days)
- MYNZ 105.1K
- CANF 412.3K
- Earning Date
- MYNZ 05-06-2025
- CANF 05-06-2025
- Dividend Yield
- MYNZ N/A
- CANF N/A
- EPS Growth
- MYNZ N/A
- CANF N/A
- EPS
- MYNZ N/A
- CANF N/A
- Revenue
- MYNZ $893,991.00
- CANF $674,000.00
- Revenue This Year
- MYNZ $42.95
- CANF $461.72
- Revenue Next Year
- MYNZ N/A
- CANF N/A
- P/E Ratio
- MYNZ N/A
- CANF N/A
- Revenue Growth
- MYNZ N/A
- CANF N/A
- 52 Week Low
- MYNZ $0.18
- CANF $1.22
- 52 Week High
- MYNZ $8.20
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- MYNZ 40.90
- CANF 37.12
- Support Level
- MYNZ $3.03
- CANF $1.14
- Resistance Level
- MYNZ $3.31
- CANF $1.27
- Average True Range (ATR)
- MYNZ 0.35
- CANF 0.12
- MACD
- MYNZ 0.06
- CANF -0.02
- Stochastic Oscillator
- MYNZ 61.80
- CANF 4.46
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).